Gabriel Blomquist
Medical · Billings, MTNPI 1659772176
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,552 of the $5,194 with a category attached, or 68.4%. Dexcom, Inc. accounts for 81.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $4,353 and has fallen 90.4% since, to $418 in 2025. Among medical clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 32 payments — averaging $162.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$4K
- Medtronic$298
- Insulet Corporation$167
- Sanofi-aventis U.S. LLC$163
- Madrigal Pharmaceuticals$125
- Lilly USA, LLC$80
- plus $148 from 3 others
What the payments were for
- Speaking & faculty fees$3,55268%
- Travel & lodging$2876%
- Food & beverage$1,35626%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 12 | $4,214 |
| Medtronic | 3 | $298 |
| Insulet Corporation | 2 | $167 |
| Sanofi-aventis U.S. LLC | 2 | $163 |
| Madrigal Pharmaceuticals | 1 | $125 |
| Lilly USA, LLC | 4 | $80 |
| Novartis | 4 | $74 |
| Novo Nordisk | 3 | $54 |
| BETA Bionics, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$3,839
- DEXCOM G6 TRANSMITTER$221
- TZIELD$136
- REZDIFFRA$125
- Omnipod$109
How this compares
$5,194 in reported general payments places this provider in the 95th percentile of 134 medical providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 175 | $220,731 |
| Tresiba Flextouch U-200Insulin Degludec | 114 | $146,811 |
| TrulicityDulaglutide | 120 | $144,090 |
| JardianceEmpagliflozin | 109 | $111,049 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 105 | $95,670 |
| Humalog Kwikpen U-200Insulin Lispro | 44 | $92,045 |
| Tresiba Flextouch U-100Insulin Degludec | 86 | $52,892 |
| MounjaroTirzepatide | 41 | $50,084 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $45,394 |
| Novolog FlexpenInsulin Aspart | 99 | $28,768 |
| FiaspInsulin Aspart (Niacinamide) | 19 | $24,380 |
| Humalog Kwikpen U-100Insulin Lispro | 59 | $20,831 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $18,650 |
| Victoza 3-PakLiraglutide | 13 | $18,576 |
| NovologInsulin Aspart | 96 | $16,967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $54 | $262,078290 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $80 | $209,888227 claims |
| Sanofi-aventis U.S. LLCLantus | $163 | $3,88633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 134 medical providers in Montana.
Other medical in Billings
- Erin LafavorBillings$6K
- Michael HinesBillings$5K
- Ashley AdamsBillings$4K
- Hans BoneBillings$3K
- Kristen KaferBillings$866
- Katherine GoynBillings$832
- Aimee Alvord BrownBillings$807
- Emma JacksonBillings$793
- Taylor PohleBillings$604
- Kellsie QuinnBillings$382
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.